SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Vasogen-- VAS on TSE
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chrisco who wrote (22)7/22/1997 9:40:00 PM
From: rohan   of 377
 
Chrisco according to the research report put out by CIBC Wood Gundy in April/97, Vasogen's double -blind controlled trial (40 patients) on Primary Raynaud's should be completed Q3/97. The report suggests that if the results are as positive as the first study trial for Raynaud's, then the way should be clear to start commercialization of Vasogen's system later in 97. There are other trial studies that should be completed with results by Q3 and Q4.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News